Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation

BACKGROUND: Cardiac glycosides are approved for the treatment of heart failure as Na(+)/K(+) pump inhibitors. Their repurposing in oncology is currently investigated in preclinical and clinical studies. However, the identification of a specific cancer type defined by a molecular signature to design...

Descripción completa

Detalles Bibliográficos
Autores principales: Da Costa, Elodie M., Armaos, Gregory, McInnes, Gabrielle, Beaudry, Annie, Moquin-Beaudry, Gaël, Bertrand-Lehouillier, Virginie, Caron, Maxime, Richer, Chantal, St-Onge, Pascal, Johnson, Jeffrey R., Krogan, Nevan, Sai, Yuka, Downey, Michael, Rafei, Moutih, Boileau, Meaghan, Eppert, Kolja, Flores-Díaz, Ema, Haman, André, Hoang, Trang, Sinnett, Daniel, Beauséjour, Christian, McGraw, Serge, Raynal, Noël J.-M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563382/
https://www.ncbi.nlm.nih.gov/pubmed/31196146
http://dx.doi.org/10.1186/s13046-019-1242-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563382/
https://www.ncbi.nlm.nih.gov/pubmed/31196146
http://dx.doi.org/10.1186/s13046-019-1242-8

Ejemplares similares